Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference

Myomo (NYSE American: MYO), a wearable medical robotics company focused on neurological disorders and upper-limb paralysis, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/31/2025 - 04:05 PM EDT

BURLINGTON, Mass.--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24^th Annual Needham Virtual Healthcare Conference, being held from April 7^th to April 10^th, and will be holding one-on-one meetings with investors registered with the conference. The presentation will be webcast live at 3:00 p.m. ET on Thursday April 10^th. The presentation will also be archived in the Investors section of the Company’s website.

Event:	24^th Annual Needham Virtual Healthcare Conference
Date:	Thursday, April 10, 2025
Time:	3:00 p.m. ET
Webcast:	Available here

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.